NCT07535996

Brief Summary

The goal of this observational study is to understand how diet may influence the disease characteristics of inclusion body myositis (IBM). Research findings will help determine whether dietary factors could play a role in managing IBM. The study aims to answer the question: Does diet affect the muscle health and functional ability of people living with IBM? Researchers will compare adults with IBM to healthy volunteers aged 40 years and older. This comparison will help to identify which findings are related to normal ageing and which are specific to IBM. Participants will: Attend an initial screening visit at the Manchester Metropolitan University Institute of Sport to confirm eligibility and explain study procedures. Complete four weeks of home-based monitoring, including dietary records, physical activity monitoring, and questionnaires about lifestyle and symptoms. Attend a second university visit for assessments of body composition, metabolism, and muscle function.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
47

participants targeted

Target at P25-P50 for all trials

Timeline
8mo left

Started Apr 2026

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress3%
Apr 2026Dec 2026

First Submitted

Initial submission to the registry

March 12, 2026

Completed
1 month until next milestone

First Posted

Study publicly available on registry

April 17, 2026

Completed
13 days until next milestone

Study Start

First participant enrolled

April 30, 2026

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

April 17, 2026

Status Verified

March 1, 2026

Enrollment Period

8 months

First QC Date

March 12, 2026

Last Update Submit

April 10, 2026

Conditions

Keywords

Inclusion Body MyositisIBMSkeletal muscleAgingMuscle functionMuscle strengthCase-control studyDietNutrition

Outcome Measures

Primary Outcomes (10)

  • Habitual Daily Protein Intake

    Habitual daily protein intake (g/day) estimated using two 3-day weighed food diaries.

    Baseline

  • Habitual Daily Protein Intake Relative to Body Mass

    Mean daily protein intake estimated using two 3-day weighed food diaries, normalised to body mass (g/kg/day).

    Baseline

  • Appendicular Lean Mass

    Appendicular lean mass (kg) measured using dual-energy X-ray absorptiometry (DXA). Appendicular lean mass represents the sum of lean soft tissue mass from both arms and both legs.

    Baseline

  • Handgrip Strength

    Maximal isometric handgrip strength (kg) measured using a hand-held dynamometer. Participants perform three maximal voluntary contractions with each hand; the highest value recorded is used for analysis.

    Baseline

  • Peak Knee Extensor Torque

    Peak knee extensor torque (Nm) represents the highest rotational force generated during knee extension across five maximal repetitions using an isokinetic dynamometer.

    Baseline

  • Peak Knee Flexor Torque

    Peak knee flexor torque (Nm) represents the highest rotational force generated during knee flexion across five maximal repetitions using an isokinetic dynamometer.

    Baseline

  • sporadic Inclusion Body Myositis Functional Assessment (sIFA)

    Functional status as determined by the sIFA total score. The sIFA is an 11-item patient-reported outcome measure evaluating functional ability in individuals with inclusion body myositis, including swallowing, mobility, and hand function. Each item is scored on a 0-10 scale, and item scores are summed to produce a total score ranging from 0 to 110. Lower scores indicate greater functional impairment, while higher scores indicate better functional ability.

    Baseline

  • Activities of Daily Living: Nottingham Extended Activities of Daily Living Scale (NEADL) Total Score

    Functional independence measured using NEADL scale. The NEADL is a 22-item patient-reported questionnaire covering mobility, kitchen activities, domestic activities, and leisure activities. Each item is scored from 0 to 3, representing increasing levels of independence. Item scores are summed to produce a total score ranging from 0 to 66, with higher scores indicating greater independence in activities of daily living and lower scores indicating greater functional limitation.

    Baseline

  • Muscle Functional Cross-Sectional Area

    Functional cross-sectional area (cm²) of skeletal muscle derived from magnetic resonance imaging (MRI). Functional cross-sectional area represents the estimated contractile muscle area and is calculated from total muscle cross-sectional area adjusted for intramuscular fat fraction.

    Baseline

  • Skeletal Muscle Volume

    Muscle volume (cm³) derived from magnetic resonance imaging (MRI) of the thigh and forearm muscles using image segmentation techniques.

    Baseline

Secondary Outcomes (24)

  • Broader Nutrient Intake

    Baseline

  • Serum 25-Hydroxyvitamin D Concentration

    Baseline

  • Resting Energy Expenditure

    Baseline

  • Physical Activity Scale for Individuals with Physical Disabilities (PASIPD) Total Score

    Baseline

  • Total Energy Intake

    Baseline

  • +19 more secondary outcomes

Study Arms (2)

IBM

Individuals living with Inclusion Body Myositis

Radiation: Whole-Body Dual-Energy X-ray AbsorptiometryOther: AnthropometryOther: Capillary Blood SamplingOther: Indirect CalorimetryOther: Magnetic Resonance ImagingOther: DynamometryOther: Behavioural Monitoring

Healthy Controls

Adults without diagnosed neuromuscular or relevant chronic disease, matched to participants with IBM by age, sex, and habitual physical activity level

Radiation: Whole-Body Dual-Energy X-ray AbsorptiometryOther: AnthropometryOther: Capillary Blood SamplingOther: Indirect CalorimetryOther: Magnetic Resonance ImagingOther: DynamometryOther: Behavioural Monitoring

Interventions

A total body exposure scan to yield measurements of whole-body and regional body composition, including total fat mass, appendicular fat-free mass, bone mineral content, and bone mineral density.

Healthy ControlsIBM

Heights and weight measurements.

Healthy ControlsIBM

A finger-prick blood sample to assess serum 25-hydroxyvitamin D concentrations.

Healthy ControlsIBM

Resting energy expenditure measurement via indirect calorimetry.

Healthy ControlsIBM

Magnetic resonance imaging to assess muscle morphology and swallowing-related structures.

Healthy ControlsIBM

A hand-held dynamometer will be used to assess grip strength. An isokinetic dynamometer will be used to assess knee flexor and extensor strength.

Healthy ControlsIBM

Encompassing food records, dual accelerometery and questionnaires, including a food frequency questionnaire, the sIBM Physical Functioning Assessment (s-IFA), the Physical Activity Scale for Individuals with Physical Disabilities (PASIPD), a quality of life questionnaire (Short Form-36v2), the Nottingham Extended ADL Scale, Modified Fatigue Impact Scale (MFIS), a visual analogue scale for pain, the Pittsburgh Sleep Quality Index (PSQI) and SWAL-QOL questionnaires.

Healthy ControlsIBM

Eligibility Criteria

Age40 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults aged 40 years and older will be recruited into two groups: individuals with a confirmed diagnosis of IBM and healthy volunteers without diagnosed neuromuscular or relevant chronic disease. Participants with IBM will be identified through specialist neuromuscular services in the UK, and control participants will be recruited from the local community. Control participants will be frequency-matched to the IBM group by age, sex, and habitual physical activity level.

You may qualify if:

  • Age: Adults aged ≥40 years at the time of consent.
  • Ability to Provide Informed Consent: Participants must be cognitively capable of providing written, informed consent.
  • Disease Progression: Participants must be able to walk short distances, with or without the use of an assistive aid (e.g., a cane or frame) for balance, so that they can undertake study procedures without safety concerns. Must be able to consume solid or modified-texture food, with or without dysphagia adaptations (i.e., not exclusively tube-fed).
  • Willingness to Participate: Willing to attend study visits and comply with all study procedures.
  • Disease-Free: Control participants must be generally healthy, with no known myopathies or metabolic diseases. They must not have any conditions that, in the judgement of a clinician, would compromise their safety, impair their ability to complete study procedures, or influence study outcomes.
  • Age: Adults aged ≥40 years at the time of consent.
  • Ability to Provide Written Informed Consent
  • Willingness to Participate
  • Matched to IBM participants according to their age and physical activity levels

You may not qualify if:

  • Coexisting Neuromuscular or Metabolic Disorders: Presence of other neuromuscular or metabolic disorders that may confound the outcomes of interest.
  • Severe Dysphagia: Participants requiring exclusive enteral or parenteral feeding, which would prevent participation in dietary intake assessments.
  • Enrolment in an interventional trial within the past 3 months: Participation in an interventional study within the past 3 months involving interventions that may affect dietary habits, physical activity, or muscle metabolism.
  • Contraindications to any Study Procedures: Any condition preventing safe completion of key assessments. For instance: severe osteoporosis contraindicating DXA scanning (T-score \< -3.0), respiratory conditions, severe claustrophobia, severe cognitive impairments or communication barriers that may impair participant ability to comply with study procedures.
  • Logistical Concerns: Any other logistical concern, as judged by the CI, that would compromise participant safety or the integrity of study data.
  • English Comprehension: Participants will be excluded if they are unable to understand written or verbal English to a degree that would impair their ability to provide informed consent or fully understand the study procedures.
  • Diagnosed neuromuscular or metabolic Disorder
  • Enrolment in an interventional trial within the past 3 months
  • Contraindications to any study procedures such as those listed for IBM participants (e.g., DXA, MRI).
  • Logistical or safety concerns, as judged by the research team.
  • To minimise dietary overlap, individuals living in the same household as an IBM participant will not be eligible.
  • Do not meet the physical activity criteria to be appropriately matched to an IBM participant
  • Unable to understand written or verbal English

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Manchester Metropolitan University Institute of Sport

Manchester, M17EL, United Kingdom

Location

MeSH Terms

Conditions

Myositis, Inclusion Body

Interventions

AnthropometryCalorimetry, IndirectMagnetic Resonance Spectroscopy

Condition Hierarchy (Ancestors)

MyositisMuscular DiseasesMusculoskeletal DiseasesNeuromuscular DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

Physical ExaminationDiagnostic Techniques and ProceduresDiagnosisInvestigative TechniquesBiometryEpidemiologic MeasurementsPublic HealthEnvironment and Public HealthCalorimetryChemistry Techniques, AnalyticalSpectrum Analysis

Study Officials

  • Paul T Morgan, PhD

    Manchester Metropolitan University

    STUDY DIRECTOR

Central Study Contacts

Charlotte Emily Linscott, BSc

CONTACT

Dr Paul T Morgan, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 12, 2026

First Posted

April 17, 2026

Study Start

April 30, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

April 17, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will share

De-identified individual participant data from all study assessments will be shared.

Shared Documents
STUDY PROTOCOL, SAP, ICF, ANALYTIC CODE
Time Frame
De-identified individual participant data and supporting materials will be made available following publication of the primary study results and will remain available indefinitely.
Access Criteria
Access to de-identified individual participant data and supporting materials will be available to any member of the public, including researchers, clinicians, and other stakeholders. Materials will be hosted in an open-access repository (Open Science Framework) and can be downloaded directly from the project page. Data will be available in standard file formats (e.g., CSV, PDF, or R/Python code files) with a README describing variable definitions, units, and coding to ensure usability and reproducibility.

Locations